Related trials
IMPROVE-IT, 2014 - ezetimibe vs control
AIM-HIGH, 2011 - niacin vs placebo (on top statin)
ACCORD lipid, 2010 - fenofibrate vs placebo (on top simvastatine)
SHARP, 2010 - ezetimibe+simvastatin vs placebo
ARBITER-HALTS 6, 2010 - ezetimibe vs niacin
SEARCH, 2010 - simvastatin high dose vs simvastatin
Oxford Niaspan Study, 2009 - niacin vs placebo (on top statin)
Emmerich, 2009 - etofibrate vs placebo
ARBITER 6-HALTS (niacin vs ezetimibe), 2009 - niacin vs ezetimibe
ARBITER 2, 2009 - niacin vs placebo (on top statin)
GISSI-HF rosuvastatine, 2008 - rosuvastatin vs placebo
JUPITER, 2008 - rosuvastatin vs placebo
SANDS, 2008 - aggressive treatment vs standard teatment
Tuttle, 2008 - low fat diet vs mediterranean-style diet
SAGE, 2007 - atorvastatin high dose vs pravastatin
METEOR, 2007 - rosuvastatin vs placebo
Krum, 2007 - rosuvastatin vs placebo
CORONA, 2007 - rosuvastatin vs placebo
Chello et al., 2006 - preoperative atorvastatin vs placebo
ASPEN, 2006 - atorvastatin vs placebo
SPARCL, 2006 - atorvastatin vs placebo
Patti et al., 2006 - preoperative atorvastatin vs placebo
MEGA, 2006 - pravastatin vs control
FIELD, 2005 - fenofibrate vs placebo
WHI low fat, 2005 - diet vs usual diet
See also:
All cardiovascular prevention clinical trials
All clinical trials of cholesterol lowering intervention
All clinical trials of rosuvastatin
|
|
Treatments
Studied treatment |
rosuvastatin 40mg daily
|
Control treatment |
placebo
|
Patients
Patients |
individuals, with either age (mean, 57 years) as the only coronary heart disease risk factor or a 10-year Framingham risk score of less than 10%, modest CIMT thickening (1.2-<3.5 mm), and elevated LDL cholesterol |
Method and design
Randomized effectives |
702 / 282 (studied vs. control) |
Design |
Parallel groups |
Blinding |
double-blind |
Number of centre |
61 |
Geographic area |
USA, Europe |
Primary endpoint |
carotid intima-media thickness |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
All cause death
1 / 702
0 / 282
classic
2,01 [0,03;146,84]
Cardiovascular death
0 / 702
0 / 282
classic
0,40 [0,00;102,51]
Coronary death
0 / 702
0 / 282
classic
0,40 [0,00;102,51]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
All cause death
|
1 / 702 (0,1%) |
0 / 282 (0,2%) |
0,80 |
[0,03;23,88] |
|
|
Cardiovascular death
|
0 / 702 (0,1%) |
0 / 282 (0,2%) |
0,40 |
[0,01;20,20] |
|
|
Coronary death
|
0 / 702 (0,1%) |
0 / 282 (0,2%) |
0,40 |
[0,01;20,20] |
|
|
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
0:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction (for a follow-up of )
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
Meta-analysis of all similar trials:
cholesterol lowering intervention in cardiovascular prevention for all chronical situations
Reference(s)
-
Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML.
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial..
JAMA 2007 Mar 28;297:1344-53
Pubmed
|
Hubmed
| Fulltext
|